A Phase II Study of Lenalidomide (REVLIMID) in Combination With Rituximab for Patients With CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2016
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.